Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

Table 5 Observation in patients with unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

Rate the appropriateness of the frequency of testing in an asymptomatic patientWho has had	Markers and scans
	Every 3 mo	Every 6 mo	Every 9 mo	Every 12 mo
A. No progression from prior marker and scan	7.03 (1.5)	6.53 (1.8)	5.02 (1.5)	3.52 (1.7)
B. Progression after prior marker and scan	9.03 (0.2)	6.53 (1.6)	2.01 (1.0)	1.01 (0.5)

The medians of ratings represents the type of panel consensus that was reached for the particular patient scenario (cell):

¹Median rating 1-3 and no disagreement⁴ = “inappropriate”;

²Median rating 4-6 and no disagreement⁴ = “uncertain”; and

³Median rating 7-9 and no disagreement⁴ = “appropriate”; ⁴ > 2 responses in the range 1-3 and > 2 responses in the range 7-9 = “disagreement”.